Please login to the form below
tislelizumab
This page shows the latest tislelizumab news and features for those working in and with pharma, biotech and healthcare.
Novartis and BeiGene announce positive phase 3 trial results for hepatocellular carcinoma treatment
Moreover, tislelizumab was associated with higher objective response rate – 14.3% versus 5.4% – and more durable responses – 36.1 months versus 11 months – compared with sorafenib. ... Through a collaboration and licence agreement with BeiGene in
Latest news
-
BeiGene announces positive phase 3 trial results for liver cancer treatment
The safety profile for tislelizumab was consistent with previous studies and no new safety signals were reported. ... Tislelizumab is a humanised immunoglobulin G4 monoclonal antibody designed to minimise binding to Fc gamma receptors on macrophages,
-
BeiGene and InnoRNA join to research novel mRNA therapies
Last month, BeiGene announced positive results from a phase 3 trial showing tislelizumab plus chemotherapy significantly improved overall survival for patients with advanced esophageal cancer, regardless of PD-L1 status.
-
Novartis announces positive phase 3 trial results for advanced oesophageal cancer
Results from the study showed tislelizumab plus chemotherapy significantly improved overall survival for patients, regardless of PD-L1 status. ... Through a collaboration and licence agreement with BeiGene, Novartis has the rights to develop, manufacture
-
Novartis strengthens links with BeiGene in a deal that could be worth up to $1bn
The two companies are already working together after Novartis signed an in-licensing agreement for BeiGene’s anti-PD-1 monoclonal antibody, tislelizumab. ... Novartis is advancing tislelizumab as a potential ‘bridge to enable synergistic
-
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
This is our fifth positive phase 3 readout for tislelizumab, which we are developing broadly as a potentially differentiated anti-PD-1 antibody. ... In April, BeiGene also unveiled results from a key global trial of tislelizumab in non-small cell lung
More from news
Approximately 5 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Chinese biotech’s global ambitions
The company has a PD-1 cancer immunotherapy, tislelizumab, in development in China, and believes it can compete in the market alongside multinationals MSD (Merck in the US) and BMS and ... Tislelizumab is in global phase III trials in a number of tumour
-
Biopharma's Future: Made in China
It has just submitted its PD-1 immunotherapy candidate tislelizumab with China’s regulator, and also has a late-stage BTK inhibitor to challenge J&J’s Imbruvica with a potential
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Meeting healthcare’s rising challenges
- Why female mentorship is so powerful in pharma
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
PMHub
Evoke Kyne
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
